NIPTE is partner in newly announced National Biopharmaceutical Manufacturing Institute
The participating NIPTE team will primarily focus on biopharmaceutical formulations and product development, and FDA regulatory science.
The National Institute for Pharmaceutical Technology and Education (NIPTE) is part of the newly created public-private partnership called National Institute for Innovation of Manufacturing Biopharmaceuticals (NIIMBL). Its formation was announced by US Secretary of Commerce Penny Pritzker on 16 December 2016. NIIMBL is led by the University of Delaware and includes some 150 private companies, academic institutions, and non-profit organizations across the nation. It is supported by a $70 million grant from US Department of Commerce and an initial investment of $129 million from participating organizations. Its goal is to accelerate biopharmaceutical manufacturing innovation and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing US competitiveness in this industry.
The participating NIPTE team, currently comprises six member institutions (Universities of Connecticut, Kentucky, Kansas, Texas, Iowa, and Wisconsin), is a Tier 1 partner in NIIMBL. It will hold a seat on the Institute’s Governance Board and will play a major role in its initiatives primarily focusing on biopharmaceutical formulations and product development, and FDA regulatory science. The team will work in close collaboration with three other NIPTE member institutions, Purdue University, University of Maryland, and the University of Minnesota, which are Tier 1 partners alongside NIPTE.
“We are extremely pleased that advanced pharmaceutical manufacturing is now part of the Manufacturing USA network,” said Dr Vadim J. Gurvich, executive director of NIPTE and research associate professor at the University of Minnesota. “NIIMBL’s leadership has put together a very impressive partnership that will make a significant impact on biopharmaceutical manufacturing in this nation. As a key member, we will contribute to both research and education. For example, our Center of Excellence in Pharmaceutical Formulations will be a natural partner in NIIMBL.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance